Shanghai Henlius Biotech's (HKG:2696) new drug application for HLX04-O for the treatment of wet age-related macular degeneration was accepted by China's National Medical Products Administration, a Wednesday filing with the Hong Kong bourse said.
The application is supported by a phase III study, which met its primary endpoint and exhibited a favorable safety profile.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.